LFVN
$4.67-0.06 (-1.27%)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products.
Recent News
How The LifeVantage (LFVN) Narrative Is Shifting With Reset Price Targets And Valuation Assumptions
Analysts cutting their LifeVantage price target to $7.00 are resetting expectations against a fair value anchor of $8.00 that remains unchanged. This adjustment reflects a more balanced read of recent analyst views, with some seeing room for upside while others take a cooler stance on execution risk. As you read on, you will see how these shifting targets shape the evolving narrative and what to watch next in the story. Analyst Price Targets don't always capture the full story. Head over to...
LifeVantage Conference: Subscription Sales, LoveBiome Integration, and CEO Succession in Focus
Lifevantage (NASDAQ:LFVN) executives outlined the company’s business model, product portfolio, financial profile, and growth priorities during a recent investor presentation and Q&A, highlighting a subscription-heavy revenue base, expanding product categories, and a balanced approach to capital
How The LifeVantage (LFVN) Investment Story Is Resetting After Analyst Valuation Changes
LifeVantage’s analyst price target has been reset around a model fair value of US$8.00, with the latest work keeping that headline number steady even as several underlying assumptions shift slightly. Analysts characterise this move as a reset of expectations rather than a rewrite of the story, tying the unchanged fair value to refreshed views on discount rate, revenue trajectory, profit margin and future P/E. As you read on, you will see how this updated target feeds into the ongoing bull and...
Promising Penny Stocks To Consider In February 2026
As February begins, U.S. stock indexes have shown a strong start with the Dow Jones Industrial Average climbing by 515 points and the S&P 500 nearing a record high. While larger market trends capture headlines, investors often overlook smaller opportunities such as penny stocks, which despite their vintage name, continue to offer potential for significant returns when backed by solid financials. This article explores three promising penny stocks that combine balance sheet strength with...
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks
As February begins, the U.S. stock market is showing strength, with major indexes like the Dow Jones and S&P 500 posting significant gains. In this context of rising indices, investors often look for opportunities that may offer growth potential at a lower entry cost. Penny stocks, though considered a niche investment area today, still hold promise by offering access to smaller or newer companies that can potentially deliver strong returns when backed by solid financials. Let's explore...